Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults

DNA vaccines: A safe and efficient platform technology for responding to emerging infectious diseases

(2014) Julie E. Ledgerwood et al.   Human vaccines & immunotherapeutics

DNA Priming Prior to Inactivated Influenza A(H5N1) Vaccination Expands the Antibody Epitope Repertoire and Increases Affinity Maturation in a Boost-Interval–Dependent Manner in Adults

(2013) Surender Khurana et al.   JOURNAL OF INFECTIOUS DISEASES

Prime-Boost Interval Matters: A Randomized Phase 1 Study to Identify the Minimum Interval Necessary to Observe the H5 DNA Influenza Vaccine Priming Effect

(2013) Julie E. Ledgerwood, Kathryn Zephir, Zonghui Hu, Chih-Jen Wei, LeeJah Chang, Mary E. Enama, Cynthia S. Hendel, Sandra Sitar, Robert T. Bailer, Richard A. Koup, John R. Mascola, Gary J. Nabel, Barney S. Graham et al.   JOURNAL OF INFECTIOUS DISEASES

DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial

(2013) Barney S. Graham et al.   PLoS One

Seasonal Trivalent Inactivated Influenza Vaccine Protects against 1918 Spanish Influenza Virus Infection in Ferrets

(2012) M. B. Pearce et al.   JOURNAL OF VIROLOGY

A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial

(2011) Julie E. Ledgerwood et al.   JOURNAL OF INFECTIOUS DISEASES

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials

(2011) Julie E Ledgerwood et al.   LANCET INFECTIOUS DISEASES

Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis

(2011) Michael T Osterholm et al.   LANCET INFECTIOUS DISEASES

In Vivo Electroporation Enhances the Immunogenicity of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers

(2011) Sandhya Vasan et al.   PLoS One

Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin

(2010) Larry R. Smith et al.   VACCINE

Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials

(2009) Eric Plennevaux et al.   LANCET

Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009–10 influenza season: a multicentre, randomised controlled trial

(2009) Zoltan Vajo et al.   LANCET

Response to a Monovalent 2009 Influenza A (H1N1) Vaccine

(2009) Michael E. Greenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Novel Influenza A (H1N1) Vaccine in Various Age Groups

(2009) Feng-Cai Zhu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine

(2009) Tristan W. Clark et al.   NEW ENGLAND JOURNAL OF MEDICINE

Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

Cross-Reactive Antibody Responses to the 2009 Pandemic H1N1 Influenza Virus

(2009) Kathy Hancock et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans

(2009) R. J. Garten et al.   SCIENCE

DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial

(2009) Suzanne Jones et al.   VACCINE

A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial

(2008) Julie E. Martin et al.   VACCINE